1. Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: The early study 
Felix Ratjen, Alexander Moeller, Martha L. McKinney, Irina Asherova, Nipa Alon, Robert Maykut, Gerhild Angyalosi Olga Bede, Katalin Bolbas, Vladimir Bulatov, Elena Chertok, Carla Colombo, Michael Fayon, Ferenc Gonczi, Essam Gouda, Jutta Hammermann, Anne Munck, Melinda Solomon, John Tsanakas Felix Ratjen, Alexander Moeller, Martha L. McKinney, Irina Asherova, Nipa Alon, Robert Maykut, Gerhild Angyalosi Olga Bede, Katalin Bolbas, Vladimir Bulatov, Elena Chertok, Carla Colombo, Michael Fayon, Ferenc Gonczi, Essam Gouda, Jutta Hammermann, Anne Munck, Melinda Solomon, John Tsanakas 
Journal of Cystic Fibrosis 
Volume 18, Issue 1, Pages (January 2019)
DOI: /j.jcf
Copyright © 2018 European Cystic Fibrosis Society Terms and Conditions

2. Fig. 1
EARLY study design.
Bid, twice daily; DB, double blind; OL, open label; Pa, Pseudomonas aeruginosa; TOBI, tobramycin inhalation solution; Tx, treatment.
Journal of Cystic Fibrosis  , 78-85DOI: ( /j.jcf )
Copyright © 2018 European Cystic Fibrosis Society Terms and Conditions

3. Fig. 2 Patient disposition.
⁎One patient entered the follow-up period after discontinuing the DB period.
DB, double-blind; OL, open label; Pa, Pseudomonas aeruginosa; SAE, serious adverse event; TOBI, tobramycin inhalation solution.
Journal of Cystic Fibrosis  , 78-85DOI: ( /j.jcf )
Copyright © 2018 European Cystic Fibrosis Society Terms and Conditions

4. Fig. 3
Proportion of Pa-negative patients (observed cases, no imputation).
⁎Of 25 patients from the placebo group, 1 patient discontinued because of serious adverse events.
†Of 8 Pa-negative patients, only 5 entered follow-up; for the other 3 patients, reason for not entering follow-up was not reported.
DB, double-blind; OL; open-label; Pa, Pseudomonas aeruginosa; TOBI, tobramycin inhalation solution, Tx, treatment.
Journal of Cystic Fibrosis  , 78-85DOI: ( /j.jcf )
Copyright © 2018 European Cystic Fibrosis Society Terms and Conditions